论文部分内容阅读
目的 :评价 NVB联合顺铂治疗晚期非小细胞肺癌的疗效和毒副作用。方法 :收集晚期非小细胞肺癌患者 94例 ,给予 NVB+DDP化疗 ,第 1天、第 8天静脉滴注 NVB 4 0 mg,第 1天到第3天静脉滴注 DDP 5 0 mg,3周为 1周期 ,2周期后评价疗效。结果 :本组 94例 NSCL C患者中 ,总有效率 (CR+PR) 4 7.8% ,其中初治 5 0 .0 % ,复治病例 4 6 .7% ,初、复治病例间无显著性差异 (P>0 .0 5 ) ,毒副作用主要是骨髓抑制、局部刺激。结论 :NVB+DDP治疗晚期非小细胞肺癌有较好的临床疗效 ,特别是对复发病例也有较好疗效 ,毒副作用能够耐受 ,有较好的临床应用价值。
Objective: To evaluate the efficacy and side effects of NVB combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods: Ninety-four patients with advanced non-small cell lung cancer were enrolled in this study. NVB + DDP chemotherapy was given. Intravenous NVB 40 mg was given on day 1 and day 8, DDP 50 mg on day 1 to day 3, 1 cycle, 2 cycles after the evaluation of efficacy. Results: The total effective rate (CR + PR) was 94.8% in 94 NSCL C patients in this study, of which 50.0% of the patients were initially treated and 46.7% of the patients were re-treated, there was no significant difference between the initial and re-treatment cases The differences (P> 0.05), the main side effects of bone marrow suppression, local stimulation. Conclusions: NVB + DDP has a good clinical curative effect in the treatment of advanced non-small cell lung cancer, especially in the relapse cases. The toxic side effects are tolerable and have good clinical value.